Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies-Reference-Cited by-同舟云学术

Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies

Published:2020-11-20 Issue:1 Volume:193 Page:15-25
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Danilov Alexey V.¹^ORCID,Persky Daniel O.²^ORCID

Affiliation:

1. City of Hope National Medical Center Duarte CAUSA

2. The University of Arizona Cancer Center Tucson AZ USA

Funder

Leukemia and Lymphoma Society

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17184

Reference104 articles.

1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2. The clinical and epidemiological burden of chronic lymphocytic leukaemia

3. American Cancer Society.Key statistics for chronic lymphocytic leukemia.https://www.cancer.org/cancer/chronic‐lymphocytic‐leukemia/about/key‐statistics.html(2020 accessed March 3 2020).

4. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

5. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms;International Journal of Molecular Sciences;2024-03-12

2. Modern approach to the treatment of chronic lymphocytic leukemia;Onkologie;2023-10-05

3. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review;Current Cardiology Reviews;2023-05

4. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors;Expert Opinion on Drug Safety;2023-04-19

5. Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL);Expert Review of Pharmacoeconomics & Outcomes Research;2023-04-11